As of 2025-05-16, the Fair Value of Y-mAbs Therapeutics, Inc (YMAB) is -3.28 USD. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 3.86 USD, the upside of Y-mAbs Therapeutics, Inc is -184.87%.
With the market price of 3.86 USD and our fair value calculation, Y-mAbs Therapeutics, Inc (YMAB) is not a good investment. Investing in YMAB stocks now will result in a potential loss of 184.87%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 5Y Avg | |
| Net income | -119.34 | -55.28 | -95.57 | -21.43 | -29.67 | -64.26 |
| YoY growth | -47.28% | 53.68% | -72.88% | 77.58% | -38.45% | -5.47% |
| Market Cap (mil) | 174.78 |
| P/E | |
| Forward P/E |
| EPS | -0.66 |
| Avg earnings growth rate | -5.47% |
| TTM earnings | -29.67 |